HUGE Stock Overview
About the company
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD201, a palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. is headquartered in Toronto, Canada.
Capture your thoughts, links and company narrative
FSD Pharma Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.95|
|52 Week High||CA$2.57|
|52 Week Low||CA$0.92|
|1 Month Change||-20.41%|
|3 Month Change||85.71%|
|1 Year Change||77.27%|
|3 Year Change||-59.46%|
|5 Year Change||n/a|
|Change since IPO||-91.92%|
Recent News & Updates
|HUGE||CA Pharmaceuticals||CA Market|
Return vs Industry: HUGE exceeded the Canadian Pharmaceuticals industry which returned -63.1% over the past year.
Return vs Market: HUGE exceeded the Canadian Market which returned -12% over the past year.
|HUGE Average Weekly Movement||9.5%|
|Pharmaceuticals Industry Average Movement||12.6%|
|Market Average Movement||9.2%|
|10% most volatile stocks in CA Market||18.0%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: HUGE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: HUGE's weekly volatility (10%) has been stable over the past year.
FSD Pharma Inc. Fundamentals Summary
|HUGE fundamental statistics|
Is HUGE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HUGE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.66|
|Net Profit Margin||0.00%|
How did HUGE perform over the long term?See historical performance and comparison